Campbell & CO Investment Adviser LLC Takes $111,000 Position in Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

Campbell & CO Investment Adviser LLC purchased a new stake in shares of Merrimack Pharmaceuticals Inc (NASDAQ:MACK) in the third quarter, according to its most recent 13F filing with the SEC. The fund purchased 24,682 shares of the biopharmaceutical company’s stock, valued at approximately $111,000. Campbell & CO Investment Adviser LLC owned approximately 0.18% of Merrimack Pharmaceuticals at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. grew its position in Merrimack Pharmaceuticals by 41.7% in the second quarter. Jacobs Levy Equity Management Inc. now owns 34,439 shares of the biopharmaceutical company’s stock worth $208,000 after acquiring an additional 10,139 shares in the last quarter. Citadel Advisors LLC purchased a new position in Merrimack Pharmaceuticals in the second quarter worth $82,000. Vanguard Group Inc. grew its position in Merrimack Pharmaceuticals by 67.6% in the second quarter. Vanguard Group Inc. now owns 377,010 shares of the biopharmaceutical company’s stock worth $2,281,000 after acquiring an additional 152,080 shares in the last quarter. Finally, Nuveen Asset Management LLC purchased a new position in Merrimack Pharmaceuticals in the second quarter worth $2,867,000. Hedge funds and other institutional investors own 48.28% of the company’s stock.

Separately, ValuEngine upgraded shares of Merrimack Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, September 30th.

Shares of NASDAQ:MACK opened at $4.17 on Wednesday. Merrimack Pharmaceuticals Inc has a 52-week low of $3.70 and a 52-week high of $7.50. The firm has a fifty day moving average of $5.01 and a 200 day moving average of $5.78.

Merrimack Pharmaceuticals Profile

Merrimack Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers. The company is developing MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to treat patients with solid tumors. Its preclinical product candidates include MM-401, an agonistic antibody targeting a novel immuno-oncology target; and MM-201, a stabilized agonist-Fc fusion protein targeting death receptors 4 and 5.

Read More: Equity Income

Want to see what other hedge funds are holding MACK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merrimack Pharmaceuticals Inc (NASDAQ:MACK).

Institutional Ownership by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)

Receive News & Ratings for Merrimack Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit